Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk Unveils Up to 50% US Price Cut for Wegovy, Ozempic
02:48pm, Tuesday, 24'th Feb 2026
Novo Nordisk (NVO) is moving to recalibrate its position in the US obesity market, outlining plans to lower the list prices of its semaglutide medicines beginni
Eli Lilly Drops After Novo Nordisk Unleashes Massive GLP-1 Price Cuts
02:47pm, Tuesday, 24'th Feb 2026
Eli Lilly (LLY) shares fell 2% on Tuesday morning after rival Novo Nordisk (NVO) said it plans to reduce U.S. list prices for several widely used diabetes and o
Novo Nordisk to slash list prices of Ozempic, Wegovy by up to 50%
01:51pm, Tuesday, 24'th Feb 2026
Novo Nordisk announced up to 50% price cuts for Ozempic and Wegovy diabetes and weight-loss drugs starting January 2027, lowering costs to $675 per dose.
Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026
01:01pm, Tuesday, 24'th Feb 2026
LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.
Anthropic's enterprise showcase impressed the room but is the AI threat to software stocks remains largely a ghost story?
12:08pm, Tuesday, 24'th Feb 2026
The demos were real. The use cases were compelling.
Stock Market Today: Major Indexes Rise After Tumbling Monday; AMD Stock Surges on Meta Chips Deal
10:30am, Tuesday, 24'th Feb 2026
Major stock indexes gained in early trading Tuesday, a day after plunging on worries about AI disruption and uncertainty over the state of President Donald Trump's tariffs.
Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound
09:15am, Tuesday, 24'th Feb 2026
The failure of its next-generation obesity drug to match Eli Lilly's blockbuster has blown a hole in Novo's post-Ozempic strategy, with analysts slashing price targets and two major banks walking away
Ozempic And Wegovy Prices Will Be Cut Next Year, Drug-Maker Says
09:00am, Tuesday, 24'th Feb 2026
“The lower list price is intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductibl
Novo Nordisk: Investors Focusing On CagriSema Results Are Missing The Big Picture
09:00am, Tuesday, 24'th Feb 2026
Novo Nordisk A/S remains a buy despite CagriSema's failure to match tirzepatide in head-to-head trials, as the market overreacts to short-term setbacks. NVO's oral Wegovy pill is poised to drive futur
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
08:54am, Tuesday, 24'th Feb 2026
Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027. The move aims to make the treatments more ac
Novo Nordisk to cut US list prices of Ozempic, Wegovy as of 2027
08:10am, Tuesday, 24'th Feb 2026
Danish drugmaker Novo Nordisk said on Tuesday it plans to slash the U.S. list prices of its blockbuster weight-loss drug Wegovy and diabetes drug Ozempic by up to 50% and 35% respectively as of Januar
Novo Nordisk and Eli Lilly shares both fall after Ozempic price-cut plan
07:51am, Tuesday, 24'th Feb 2026
Shares of Novo Nordisk and rival Eli Lilly fell on Tuesday after a report said price cuts are coming for the popular weight-loss drugs.
Novo Nordisk to slash US list prices of Ozempic and Wegovy, WSJ reports
07:42am, Tuesday, 24'th Feb 2026
Danish drugmaker Novo Nordisk plans to slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year, the Wall Street Journal reported on
First Look: Gilead buys Arcellx; IBM sinks on AI; Bitcoin slides
07:37am, Tuesday, 24'th Feb 2026
Stock News Dimon warns on credit cycle: JPMorgan Chase (JPM) CEO Jamie Dimon cautioned that elevated asset prices and growing banking competition echo preâ200
Novo Nordisk will slash the list prices for its popular drugs Wegovy and Ozempic by as much as half starting next year
07:30am, Tuesday, 24'th Feb 2026
The reductions will take effect next January, and both Ozempic and Wegovy will list for $675 a month.
